iX Biopharma Ltd. (42C) AI Stock Analysis

• Market Cap: S$117.59M
• Dividend Yield: N/A
• Average Volume (3M): 15.11M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.04
• Revenue Growth: 30.34%
• EPS Growth: 17.14%
• Country: SG
• Employees: 35
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 955,980,800
• 10 Day Avg. Volume: 11,332,920
• 30 Day Avg. Volume: 15,113,843
• PEG Ratio: 0.08
• Price to Book (P/B): 38.32
• Price to Sales (P/S): 1.80
• P/FCF Ratio: -3.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: S$0.13 ▲(4.17% Upside)

The overall stock score of 52 reflects significant financial challenges, with persistent losses and weak financial health being the most impactful factors. While technical indicators show a bullish trend, the poor valuation due to negative earnings and lack of dividends further weighs down the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for iX Biopharma's products, suggesting effective market penetration and potential for future expansion.

Innovative Drug Delivery

The unique sublingual delivery technology enhances drug bioavailability, providing a competitive edge in the pharmaceutical industry and addressing unmet medical needs.

Product Pipeline

A diverse product pipeline targeting critical health issues positions iX Biopharma for long-term growth and relevance in the pharmaceutical sector.

Negative Factors

High Leverage

High leverage poses financial risk, limiting flexibility and increasing vulnerability to market fluctuations, which may impact long-term stability.

Negative Cash Flows

Negative cash flows indicate potential liquidity issues, which can hinder the company's ability to invest in growth opportunities and meet financial obligations.

Weak Profitability

Persistent losses and weak margins reflect operational inefficiencies, challenging iX Biopharma's ability to achieve sustainable profitability and shareholder returns.

iX Biopharma Ltd. Business Overview & Revenue Model

Company Description

iX Biopharma Ltd. (42C) is a biopharmaceutical company based in Singapore that specializes in the development and commercialization of innovative therapeutics and drug delivery systems. The company primarily focuses on creating proprietary drug formulations that leverage its unique sublingual delivery technology, which enhances the bioavailability of various medications. iX Biopharma operates in the pharmaceutical sector and aims to address unmet medical needs in areas such as pain management, addiction, and other health conditions through its advanced product pipeline.

How the Company Makes Money

iX Biopharma generates revenue through the development and commercialization of its proprietary drug products, which include both prescription and over-the-counter medications. The company's revenue model includes direct sales of its products, licensing agreements, and partnerships with pharmaceutical companies for the distribution and marketing of its formulations. Additionally, iX Biopharma may receive milestone payments and royalties from collaborations that leverage its drug delivery technology. Key partnerships with industry players and continuous investment in research and development contribute significantly to its revenue streams.

iX Biopharma Ltd. Financial Statement Overview

Summary

iX Biopharma Ltd. faces significant financial challenges across all verticals. The income statement shows persistent losses and weak margins, while the balance sheet reflects high leverage and poor equity returns. Cash flow issues further exacerbate the company's financial instability, highlighting the need for strategic improvements to enhance financial health and sustainability.

Income Statement

The income statement reveals significant challenges, with consistent negative net income and declining EBIT and EBITDA margins. Despite a slight revenue growth of 5.19% in the latest year, the company struggles with profitability, as evidenced by a negative net profit margin of -130.57%. The gross profit margin improved to 26.26%, but overall, the financial health remains weak.

Balance Sheet

The balance sheet indicates high leverage, with a debt-to-equity ratio of 16.17, suggesting significant financial risk. The return on equity is negative at -27.78%, reflecting poor returns for shareholders. The equity ratio is low, indicating a heavy reliance on debt financing, which could be risky if not managed properly.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a concerning free cash flow growth rate of -18.61%. The operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is slightly positive at 1.05, but overall cash flow management appears weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.77M	7.77M	5.96M	5.91M	14.39M	1.75M
Gross Profit	2.04M	2.04M	1.05M	2.32M	12.29M	-382.00K
EBITDA	-5.87M	-8.96M	-8.68M	-8.51M	-2.84M	-10.79M
Net Income	-10.14M	-10.14M	-10.79M	-9.62M	-4.60M	-8.23M
Balance Sheet
Total Assets	11.28M	11.28M	14.62M	24.93M	28.52M	18.86M
Cash, Cash Equivalents and Short-Term Investments	866.00K	866.00K	1.77M	6.52M	13.49M	6.21M
Total Debt	5.90M	5.90M	5.20M	4.34M	4.41M	4.24M
Total Liabilities	10.92M	10.92M	10.28M	9.08M	8.77M	7.15M
Stockholders Equity	365.00K	365.00K	4.34M	15.85M	19.74M	11.71M
Cash Flow
Free Cash Flow	-3.96M	-3.96M	-6.84M	-8.36M	2.92M	-8.90M
Operating Cash Flow	-3.76M	-3.76M	-6.55M	-7.66M	3.12M	-8.35M
Investing Cash Flow	-201.00K	-201.00K	1.06M	-695.00K	-5.62M	-507.00K
Financing Cash Flow	3.12M	3.12M	724.00K	1.42M	9.79M	10.02M

iX Biopharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42C, the sentiment is Positive. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.09, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.38 is Neutral, neither overbought nor oversold. The STOCH value of -14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:42C.

iX Biopharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
42C	52 Neutral	S$117.59M	―	-431.07%	―	30.34%	17.14%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

iX Biopharma Ltd. Corporate Events

iX Biopharma Enters Joint Venture to Expand US Market Presence

iX Biopharma Ltd. has entered into a non-binding term sheet with Orion Specialty Labs, LLC to establish a joint venture aimed at manufacturing and commercializing its WaferiX®-based pharmaceutical and supplement products in the USA. The joint venture will be capital-light, with iX retaining 75% control and strategic oversight. Orion will fund new manufacturing equipment and operating capital, facilitating immediate market reach through its 503B network and GLD’s affiliated 503A network. This venture allows iX to expand its market presence in the USA without capital outlay, while Orion gains access to innovative sublingual formulations, enhancing its market position.

iX Biopharma Partners with Orion to Launch WaferiX® in U.S.

iX Biopharma Ltd has entered into a strategic partnership with Orion Specialty Labs to commercialize its WaferiX® portfolio in the U.S., marking a significant shift from research to commercialization. This capital-light joint venture allows iX Biopharma to access Orion’s FDA-licensed compounding network, facilitating rapid market entry without further clinical trials, and positioning the company to capture a significant share of the growing U.S. compounding market, projected to exceed US$10 billion by 2033.

iX Biopharma Secures S$6.7 Million for U.S. Market Expansion

iX Biopharma Ltd. has successfully raised S$6.7 million through an upsized share placement, surpassing its initial target of S$5.0 million due to strong investor demand. The funds will support the company’s strategic expansion into the U.S. market, leveraging its compounding pharmacy model to commercialize novel sublingual products without additional R&D costs. This move is expected to strengthen iX Biopharma’s position in the world’s largest healthcare market and drive its next phase of growth, focusing on its compounding, wellness, and drug development divisions.

iX Biopharma to Raise S$5 Million via Share Placement

iX Biopharma Ltd. has entered into a placement agreement with Oversea-Chinese Banking Corporation Limited to raise a minimum of S$5,000,000 through the issuance of new ordinary shares. This strategic move aims to enhance the company’s capital structure by offering shares that will constitute approximately 5.33% of its enlarged share capital. The placement is structured as an exempt offering in Singapore, targeting institutional and accredited investors, and is expected to bolster the company’s financial position, potentially impacting its market operations and investor relations positively.